Texosome-based+drug+delivery+system+for+cancer+therapy：from+past+to+present.pdfVIP

Cancer Biol Med 2015;12:150-162. doi: 10.7497/j.issn.2095-3941.2015.0045 REVIEW Texosome-based drug delivery system for cancer therapy: from past to present 1 1 2 1 Hamideh Mahmoodzadeh Hosseini , Raheleh Halabian , Mohsen Amin , Abbas Ali Imani Fooladi 1Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran 1435916471, Iran; 2 Department of Drug and Food Control, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 1417653861, Iran ABSTRACT Rising worldwide cancer incidence and resistance to current anti-cancer drugs necessitate the need for new pharmaceutical compounds and drug delivery system. Malfunction of the immune system, particularly in the tumor microenvironment, causes tumor growth and enhances tumor progression. Thus, cancer immunotherapy can be an appropriate approach to provoke the systemic immune system to combat tumor expansion. Texosomes, which are endogenous nanovesicles released by all tumor cells, contribute to cell-cell communication and modify the phenotypic features of recipient cells due to the texosomes’ ability to transport biological components. For this reason, texosome-based delivery system can be a valuable strategy for therapeutic purposes. To improve the pharmaceutical behavior of this system and to facilitate its use in medical applications, biotechnology approaches and mimetic techniques have been utilized. In this review, we present the development history of texosome-based delivery systems and discuss the advantages and disadvantages of each system. KEYWORDS Cancer thera